These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 383292)

  • 1. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
    Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
    Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early pulmonary toxicity after administration of high-dose BCNU.
    Litam JP; Dail DH; Spitzer G; Vellekoop L; Verma DS; Zander AR; Dicke KA
    Cancer Treat Rep; 1981; 65(1-2):39-44. PubMed ID: 6261949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.
    Negrier S; Ranchere JY; Philip I; Merrouche Y; Biron P; Blaise D; Attal M; Rebattu P; Clavel M; Pourreau C
    Bone Marrow Transplant; 1991 Oct; 8(4):259-64. PubMed ID: 1756323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
    Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
    Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cytoreductive therapy with autologous bone marrow transplantation in advanced malignancies.
    Barbasch A; Higby DJ; Brass C; Bakri K; Karakousis C; Pontes JE; Wajsman LZ; Beckley S; Freeman A; Killion K; Burnett D
    Cancer Treat Rep; 1983 Feb; 67(2):143-8. PubMed ID: 6337711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) autologous bone marrow transplantation therapy of refractory cancer: a preliminary report.
    Phillips GL; Fay JW; Herzig GP; NaPombejara C; Wolff SN
    Exp Hematol; 1979; 7 Suppl 5():372-83. PubMed ID: 400699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
    Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
    Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
    J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.
    Panella TJ; Smith DC; Schold SC; Rogers MP; Winer EP; Fine RL; Crawford J; Herndon JE; Trump DL
    Cancer Res; 1992 May; 52(9):2456-9. PubMed ID: 1533174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.